Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Roger Aston
Date of last notice	13 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	26 March 2019
No. of securities held prior to change	10,746,296 Ordinary Fully Paid Shares 1,791,050 Unlisted Options 30/09/2016 12c
Class	Ordinary Fully Paid Shares
Number acquired	4,298,519 Ordinary Fully Paid Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$107,462.98
No. of securities held after change	15,044,815 Ordinary Fully Paid Shares 913,222 Unlisted Options 30/09/2016 – 12c
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Rights Issue

⁺ See chapter 19 for defined terms.

o1/o1/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
5	
(if issued securities)	
Date of change	
Dave of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
to which the interest has enanged	
Interest acquired	
interest acquired	
Interest disposed	
•	
77.1.70	
Value/Consideration	
Note: If consideration is non-cash, provide details and an	
estimated valuation	
Interest after change	
invitor and change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Robert Charles Bishop
Date of last notice	27 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.
	Mr Bishop is the sole shareholder and director of Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.
Date of change	26 March 2019
No. of securities held prior to change	6,579,328 Ordinary Fully Paid Shares 913,222 Unlisted Options 30/09/2016 – 12c
Class	Ordinary Fully Paid Shares
Number acquired	2,631,732 Ordinary Fully Paid Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$65,793.30
No. of securities held after change	9,211,060 Ordinary Fully Paid Shares 913,222 Unlisted Options 30/09/2016 – 12c
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Rights Issue

⁺ See chapter 19 for defined terms.

oı/oı/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
5	
(if issued securities)	
Date of change	
Dave of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
to which the interest has enanged	
Interest acquired	
interest acquired	
Interest disposed	
•	
77.1.70	
Value/Consideration	
Note: If consideration is non-cash, provide details and an	
estimated valuation	
Interest after change	
invitor and change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Sam Michael Wright
Date of last notice	26 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Straight Lines Consultancy Pty Ltd as trustee for the Straight Lines Trust. Mr Wright is a Director of Straight Lines Consultancy Pty Ltd and a Beneficiary of the Straight Lines Trust.
Date of change	26 March 2019
No. of securities held prior to change	2,000,000 Ordinary Fully Paid Shares 166,668 Unlisted Options 30/09/2016 – 12c
Class	Ordinary Fully Paid Shares
Number acquired	800,000 Ordinary Fully Paid Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$20,000.00
No. of securities held after change	2,800,000 Ordinary Fully Paid Shares 166,668 Unlisted Options 30/09/2016 – 12c
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Rights Issue

⁺ See chapter 19 for defined terms.

oı/oı/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Neville Bassett
Date of last notice	8 October 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
	Shares are held by Mandevilla Pty Ltd. Mr Bassett is a director and shareholder of Mandevilla Pty Ltd.
Date of change	26 March 2019
No. of securities held prior to change	5,000 Ordinary Fully Paid Shares
Class	Ordinary Fully Paid Shares
Number acquired	2,000 Ordinary Fully Paid Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$50.00
No. of securities held after change	7,000 Ordinary Fully Paid Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Rights Issue

⁺ See chapter 19 for defined terms.

o1/o1/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Detail of Contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation	
to which the interest has changed	
T 4 1 1	
Interest acquired	
Interest disposed	
77.7.76	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Communical variation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a ⁺ closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.